文献速递儿童青少年精神会诊联络精神医学

妊娠期处方兴奋剂使用与儿童神经发育障碍风险

Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

该队列研究纳入美国公开保险(2000-2018)和商业保险(2003-2020)的妊娠个体及其子女,评估妊娠后半期使用安非他明/右旋安非他明或哌甲酯与儿童神经发育障碍的关联。调整混杂因素后,安非他明/右旋安非他明暴露与任何结局均无关;哌甲酯暴露与注意缺陷多动障碍(ADHD)风险升高相关(HR 1.43),但该关联在更严格控制母亲ADHD混杂的敏感性分析中未持续。结论提示妊娠期宫内暴露于这些药物可能不会实质性增加儿童神经发育障碍风险。

要点

  • 调整混杂后,安非他明/右旋安非他明暴露与孤独症谱系障碍、ADHD及任何神经发育障碍均无显著关联。
  • 哌甲酯暴露与ADHD风险升高相关(HR 1.43),但敏感性分析中该关联未持续。
  • 未调整分析中两类兴奋剂暴露均与2-3倍风险升高相关,提示混杂因素影响显著。

核心结论

  • 妊娠期宫内暴露于安非他明/右旋安非他明或哌甲酯可能不会实质性增加儿童神经发育障碍风险。

研究设计与样本

  • 基于美国公开保险(Medicaid 2000-2018)和商业保险(MarketScan 2003-2020)的队列研究,纳入妊娠个体及链接子女。
  • 公开保险队列包括2 496 771例未暴露、4693例安非他明/右旋安非他明暴露和786例哌甲酯暴露妊娠,平均年龄25.2(6.0)岁。
  • 商业保险队列包括1 773 501例未暴露、2372例安非他明/右旋安非他明暴露和337例哌甲酯暴露妊娠,平均年龄31.6(4.6)岁。

主要发现

  • 未调整分析中,安非他明/右旋安非他明和哌甲酯暴露与所考虑的神经发育结局风险增加2-3倍相关。
  • 调整混杂后,安非他明/右旋安非他明暴露与任何结局均无关:孤独症谱系障碍HR 0.80(95%CI 0.56-1.14),ADHD HR 1.07(95%CI 0.89-1.28),任何神经发育障碍HR 0.91(95%CI 0.81-1.28)。
  • 调整后哌甲酯暴露与ADHD风险升高相关(HR 1.43;95%CI 1.12-1.82),但与孤独症谱系障碍(HR 1.06;95%CI 0.62-1.81)及任何神经发育障碍(HR 1.15;95%CI 0.97-1.36)无关。
  • 哌甲酯与ADHD的关联在更严格控制母亲ADHD混杂的敏感性分析中未持续。

临床怎么用

  • 临床咨询时可告知妊娠期使用安非他明/右旋安非他明或哌甲酯可能不会实质性增加子代神经发育障碍风险。
  • 对哌甲酯暴露与ADHD的关联需谨慎解读,因敏感性分析未持续且存在母亲ADHD混杂可能。

局限性

  • 原文未明确报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Use of medications for attention-deficit/hyperactivity disorder (ADHD) during pregnancy is increasing in the US. Whether exposure to these medications in utero impacts the risk of neurodevelopmental disorders in children is uncertain. OBJECTIVE: To evaluate the association of childhood neurodevelopmental disorders with in utero exposure to stimulant medications for ADHD. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included health care utilization data from publicly insured (Medicaid data from 2000 to 2018) and commercially insured (MarketScan Commercial Claims Database data from 2003 to 2020) pregnant individuals aged 12 to 55 years in the US with enrollment from 3 months prior to pregnancy through 1 month after delivery, linked to children. Children were monitored from birth until outcome diagnosis, disenrollment, death, or end of the study (December 2018 for Medicaid and December 2020 for MarketScan). EXPOSURES: Dispensing of amphetamine/dextroamphetamine or methylphenidate in the second half of pregnancy. MAIN OUTCOMES AND MEASURES: Autism spectrum disorder, ADHD, and a composite of any neurodevelopmental disorder were defined using validated algorithms. Hazard ratios were estimated comparing amphetamine/dextroamphetamine and methylphenidate to no exposure. RESULTS: The publicly insured cohort included 2 496 771 stimulant-unexposed, 4693 amphetamine/dextroamphetamine-exposed, and 786 methylphenidate-exposed pregnancies with a mean (SD) age of 25.2 (6.0) years. The commercially insured cohort included 1 773 501 stimulant-unexposed, 2372 amphetamine/dextroamphetamine-exposed, and 337 methylphenidate-exposed pregnancies with a mean (SD) age of 31.6 (4.6) years. In unadjusted analyses, amphetamine/dextroamphetamine and methylphenidate exposure were associated with a 2- to 3-fold increased risk of the neurodevelopmental outcomes considered. After adjustment for measured confounders, amphetamine/dextroamphetamine exposure was not associated with any outcome (autism spectrum disorder: hazard ratio [HR], 0.80; 95% CI, 0.56-1.14]; ADHD: HR, 1.07; 95% CI, 0.89-1.28; any neurodevelopmental disorder: HR, 0.91; 95% CI, 0.81-1.28). Methylphenidate exposure was associated with an increased risk of ADHD (HR, 1.43; 95% CI, 1.12-1.82]) but not other outcomes after adjustment (autism spectrum disorder: HR, 1.06; 95% CI, 0.62-1.81; any neurodevelopmental disorder: HR, 1.15; 95% CI, 0.97-1.36). The association between methylphenidate and ADHD did not persist in sensitivity analyses with stricter control for confounding by maternal ADHD. CONCLUSIONS AND RELEVANCE: The findings in this study suggest that amphetamine/dextroamphetamine and methylphenidate exposure in utero are not likely to meaningfully increase the risk of childhood neurodevelopmental disorders.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Suarez EA, Bateman BT, Hernandez-Diaz S, et al. Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children. JAMA Psychiatry. 2024. PMID: 38265792. doi:10.1001/jamapsychiatry.2023.5073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。